摘要
老年弥漫大B细胞淋巴瘤(DLBCL)患者较年轻患者预后差,这与该人群未能接受标准治疗,以及疾病本身的不良生物学特征相关。尽管R-CHOP方案(利妥昔单抗、环磷酰胺、多柔比星、长春新碱和泼尼松)是治疗老年DLBCL的一线标准,但还需结合患者的年龄、治疗耐受性、分子生物学特征、危险分层等因素综合考虑。目前老年DLBCL患者中的一线改良方案多以R-CHOP方案为基础,不断尝试添加新药单药或联合化疗,以提高该人群治疗的安全性和有效率。
Elderly patients with diffuse large B-cell lymphoma(DLBCL)have a worse prognosis than younger patients.It might be associated with the failure to receive standard care in these patients and the adverse biological characteristics of the disease.The R-CHOP(rituximab,cyclophosphamide,doxorubicin,vincristine,and prednisone)regimen is the standard first-line therapy for DLBCL.However,multiple factors such as the age of patients,the tolerance to the treatment,the molecular biological characteristics,and the risk stratification should also be considered.Currently,the modified first-line therapeutic strategies for the elderly patients with DLBCL were mostly based on the R-CHOP regimen with the addition of a single drug or chemotherapy,aiming to improve the safety and efficacy of the treatment.
作者
高弘烨
朱军
Hong-ye Gao;Jun Zhu(Department of Lymphoma,Peking University Cancer Hospital&Institute,Beijing 100142,China)
出处
《中国现代医学杂志》
CAS
北大核心
2022年第14期53-60,共8页
China Journal of Modern Medicine
基金
科技重大专项重大新药创制项目(No:2020ZX09201023)。
关键词
弥漫大B细胞淋巴瘤
老年
治疗
diffuse large B-cell lymphoma
elderly
therapy
